Pshycotropic Drugs: A Persuader for Metabolic Syndromes
Parvathi K J, Kameswaran R Ramalingam*, Sambathkumar R
Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Kumarapalayam-638183, Tamil Nadu, India
*Corresponding Author E-mail: email@example.com
Online published on 4 July, 2020.
Metabolic syndrome is a prevalent and serious disease that has been recognized recently. The term metabolic syndrome refers to a syndrome consisting of central obesity as indicated by excessive visceral fat, plasma lipid abnormalities, glucose dysregulation and high blood pressure. Schizophrenia is a dominant civil health issue that customarily nonce in the interim or anon adolescence. Antipsychotic medications is an imperative integral of the treatment of this disarray and research theorize that these drugs may be even spare constructive if given during the pioneer phase of illness. Second generation antipsychotics (SGA) have testify to scanty leverage over first generation antipsychotics(FGA) in terms of positive, negative, cognitive and affective symptoms and a lower proclivity if extrapyramidal symptoms. In contempt of these under inadmissible leverage, SGA have been associated with causing and exacerbating metabolic syndromes such as obesity, diabetes, and hyperlipidemia. Proper monitoring of metabolic parameters should be strictly followed. Life style management, drugs for controlling weight gain can be considered. There is a need for double blind studies, of long duration, with oral glucose tolerance test, other advanced tests and also to include children as group as there are reports to have a high liability for children to experience antipsychotic induced weight gain and associated metabolic disturbances.
Metabolic syndromes, Schizophrenia, Antipsychotics.